PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma — Stella

Recruiting

Back to Hodgkin Lymphoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Russia

National Medical Research Center for Hematology, Moscow

Key details

Phase

Safety & dosing

Sponsor

National Research Center for Hematology, Russia

Enrollment target

~30 participants

Started

July 2025

Primary completion

December 2027

Age range

18 Years – 60 Years

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov